Vahid Mashayekhi Goyonlo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vahid Mashayekhi Goyonlo has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Pouran Layegh
Affiliation Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publicationsYalda Nahidi
Department of Dermatology, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publicationsAli Khamesipour
Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsKlas Nordlind
Department of Medicine, Unit of Dermatology and Venereology, Solna, Karolinska Instititutet, Stockholm, Sweden
2 shared publicationsMasoud Maleki
Department of Dermatology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publicationsMona Najaf Najafi
Imam Reza Hospital Clinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications
Latest Publications
- 10 March 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 122
Identifying determinants of treatment failure with intralesional meglumine antimoniate in patients with cutaneous leishmaniasis
- 10 March 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 122
Identifying determinants of treatment failure with intralesional meglumine antimoniate in patients with cutaneous leishmaniasis
- Open Access
- 11 September 2025
- Published by Springer Nature in Parasitology Research
- Vol. 124 (9) , 1-7
Comparison of the efficacy of local thermotherapy versus Glucantime® in the treatment of anthroponotic cutaneous leishmaniasis: a pilot study
This pilot study is the first in Iran that evaluates the effectiveness of thermotherapy compared to intralesional Glucantime® in the treatment of cutaneous leishmaniasis caused by Leishmania tropica. Forty patients with cutaneous leishmaniasis were separated into two groups, each consisting of 20 patients. The control group received intralesional Glucantime® weekly for 8 weeks, while the other group received a single session of thermotherapy for each lesion using ThermoMedTM model 1.8. The patients were monitored for 6 months, during which the outcomes were evaluated by considering the dimensions, consistency, and rates of remission of the lesions. The terms “initial remission” and “complete remission” were clearly defined, and any instances of therapy failure were documented. The statistical analysis was conducted using SPSS 24.0, employing independent t-tests, chi-square tests, and ANOVA. Both treatment groups exhibited considerable decreases in lesion size and enhanced texture, with no statistically significant differences. Nevertheless, the group that underwent thermotherapy demonstrated a more significant decrease in lesion size and improvement in texture after 6 months. The remission rates were similar; however, Glucantime® achieved a faster remission. No significant side effects were recorded in either group. The present study showed that thermotherapy was equally effective as intralesional Glucantime® in treating anthroponotic leishmaniasis. Thermotherapy can be considered as an alternative, especially when Glucantime® cannot be used, even though it requires further research. Graphical abstract
- 11 September 2025
- Published by Springer Nature in Parasitology Research
- Vol. 124 (9) , 1-7
Open AccessComparison of the efficacy of local thermotherapy versus Glucantime® in the treatment of anthroponotic cutaneous leishmaniasis: a pilot study
This pilot study is the first in Iran that evaluates the effectiveness of thermotherapy compared to intralesional Glucantime® in the treatment of cutaneous leishmaniasis caused by Leishmania tropica. Forty patients with cutaneous leishmaniasis were separated into two groups, each consisting of 20 patients. The control group received intralesional Glucantime® weekly for 8 weeks, while the other group received a single session of thermotherapy for each lesion using ThermoMedTM model 1.8. The patients were monitored for 6 months, during which the outcomes were evaluated by considering the dimensions, consistency, and rates of remission of the lesions. The terms “initial remission” and “complete remission” were clearly defined, and any instances of therapy failure were documented. The statistical analysis was conducted using SPSS 24.0, employing independent t-tests, chi-square tests, and ANOVA. Both treatment groups exhibited considerable decreases in lesion size and enhanced texture, with no statistically significant differences. Nevertheless, the group that underwent thermotherapy demonstrated a more significant decrease in lesion size and improvement in texture after 6 months. The remission rates were similar; however, Glucantime® achieved a faster remission. No significant side effects were recorded in either group. The present study showed that thermotherapy was equally effective as intralesional Glucantime® in treating anthroponotic leishmaniasis. Thermotherapy can be considered as an alternative, especially when Glucantime® cannot be used, even though it requires further research. Graphical abstract
- 2 August 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (2) , 301-314
A Novel Topical Formulation of the Leishmaniasis Drug Glucantime as a Nanostructured Lipid Carrier-Based Hydrogel
: Leishmaniasis is a parasitic disease caused by Leishmania parasites. Meglumine antimoniate, or Glucantime, is the primary drug used to treat this disease. Glucantime with a standard painful injection administration route has high aqueous solubility, burst release, a significant tendency to cross into aqueous medium, rapid clearance from the body, and insufficient residence time at the injury site. Topical delivery of Glucantime can be a favorable option in the treatment of localized cutaneous leishmaniasis. In this study, a suitable transdermal formulation in the form of nanostructured lipid carrier (NLC)-based hydrogel containing Glucantime was prepared. In vitro drug release studies confirmed controllable drug release behavior for hydrogel formulation. An in vivo permeation study on healthy BALB/C female mice confirmed appropriate penetration of hydrogel into the skin and sufficient residence time in the skin. In vivo performance of the new topical formulation on the BALB/C female mice showed a significant improvement in reduction of leishmaniasis wound size, lowering parasites number in lesions, liver, and spleen compared with commercial ampule. Hematological analysis showed a significant reduction of the drug’s side effects, including variance of enzymes and blood factors. NLC-based hydrogel formulation is proposed as a new topical administration to replace the commercial ampule.
- 2 August 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 109 (2) , 301-314
A Novel Topical Formulation of the Leishmaniasis Drug Glucantime as a Nanostructured Lipid Carrier-Based Hydrogel
: Leishmaniasis is a parasitic disease caused by Leishmania parasites. Meglumine antimoniate, or Glucantime, is the primary drug used to treat this disease. Glucantime with a standard painful injection administration route has high aqueous solubility, burst release, a significant tendency to cross into aqueous medium, rapid clearance from the body, and insufficient residence time at the injury site. Topical delivery of Glucantime can be a favorable option in the treatment of localized cutaneous leishmaniasis. In this study, a suitable transdermal formulation in the form of nanostructured lipid carrier (NLC)-based hydrogel containing Glucantime was prepared. In vitro drug release studies confirmed controllable drug release behavior for hydrogel formulation. An in vivo permeation study on healthy BALB/C female mice confirmed appropriate penetration of hydrogel into the skin and sufficient residence time in the skin. In vivo performance of the new topical formulation on the BALB/C female mice showed a significant improvement in reduction of leishmaniasis wound size, lowering parasites number in lesions, liver, and spleen compared with commercial ampule. Hematological analysis showed a significant reduction of the drug’s side effects, including variance of enzymes and blood factors. NLC-based hydrogel formulation is proposed as a new topical administration to replace the commercial ampule.
- 7 June 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (6) , 1164-1166
Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran
Cutaneous leishmaniasis (CL) is a serious tropical disease and a neglected health challenge in Iran. Although limited data are available regarding anthroponotic CL, cases resistant to meglumine antimoniate (Glucantime) are increasingly being reported. Via an open-label noncontrolled case series, allopurinol (10 mg/kg/day) plus itraconazole (3–4 mg/kg/day) were orally administered for 1 month to 27 patients (56 lesions) with anthroponotic CL, most of whom were resistant to Glucantime. A mean lesion size of 3.5 ± 1.9 cm at baseline was reduced to 0.6 ± 1.0 after 1 month of treatment. Excellent treatment response was observed in 85.7% of lesions after 1 month. Recurrence only occurred in one patient in the 3-month follow-up session. This study presents preliminary evidence that oral allopurinol plus itraconazole could be an effective treatment in patients with anthroponotic CL.
- 7 June 2023
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 108 (6) , 1164-1166
Treatment of Cutaneous Leishmaniasis with Allopurinol Plus Itraconazole in Iran
Cutaneous leishmaniasis (CL) is a serious tropical disease and a neglected health challenge in Iran. Although limited data are available regarding anthroponotic CL, cases resistant to meglumine antimoniate (Glucantime) are increasingly being reported. Via an open-label noncontrolled case series, allopurinol (10 mg/kg/day) plus itraconazole (3–4 mg/kg/day) were orally administered for 1 month to 27 patients (56 lesions) with anthroponotic CL, most of whom were resistant to Glucantime. A mean lesion size of 3.5 ± 1.9 cm at baseline was reduced to 0.6 ± 1.0 after 1 month of treatment. Excellent treatment response was observed in 85.7% of lesions after 1 month. Recurrence only occurred in one patient in the 3-month follow-up session. This study presents preliminary evidence that oral allopurinol plus itraconazole could be an effective treatment in patients with anthroponotic CL.
- 15 April 2021
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 30 (3) , 335-339
Long-term successful management of an idiopathic interstitial pyogranulomatous/granulomatous dermatitis and folliculitis by omega 3 fatty acid in a dog
- 15 April 2021
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 30 (3) , 335-339
Long-term successful management of an idiopathic interstitial pyogranulomatous/granulomatous dermatitis and folliculitis by omega 3 fatty acid in a dog
- Open Access
- 19 March 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (3) , e0009241
The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
Background: Recent circumstantial evidence suggests increasing number of Iranian patients with cutaneous leishmaniasis (CL) who are unresponsive to meglumine antimoniate (MA), the first line of treatment in Iran. Oral meltifosine was previously reported to be effective in visceral leishmaniasis as well CL. The current study is designed to determine efficacy and safety of oral miltefosine for the treatment of anthroponotic cutaneous leishmaniasis (ACL) cases who were refractory to MA in Iran. Methodology/Principal findings: Miltefosine was orally administered for 27 patients with MA resistant ACL with approved L.tropica infection, at a dosage of ∼2.5 mg/kg daily for 28 days. Patients were evaluated on day 14 and 28, as well as 3, 6 and 12 month post treatment follow up sessions. Laboratory data were performed and repeated at each visit. Data were analyzed using SPSS version 17. Twenty-seven patients including 16 men (59.25%) and 11 women (40.74%) with mean age of 28.56 ± 4.8 (range 3–54 years old) were enrolled. Total number of lesions were 42 (1–4 in each patient). Most of lesions were on face (76.19%). Mean lesions’ induration size was 2.38 ± 0.73 cm at the base-line which significantly decreased to1.31 ± 0.58 cm and 0.61 ±0.49 cm after 14 and 28 days of therapy, respectively (p value <0.05). At 12-months follow-up post treatment, 22 patients had definite/partial cure (81.48%) including 17 definitely cured patients, corresponding to a cure rate of 68% on per protocol analysis, and 62.96% according to intention to treat analysis. Recurrence of lesion was only occurred in one patient (3.70%). Nausea was the most subjective complication during the therapy (33.33%). Conclusion: Oral miltefosine could be an effective alternative for the treatment of MA-resistant ACL.
- 19 March 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (3) , e0009241
Open AccessThe effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial
Background: Recent circumstantial evidence suggests increasing number of Iranian patients with cutaneous leishmaniasis (CL) who are unresponsive to meglumine antimoniate (MA), the first line of treatment in Iran. Oral meltifosine was previously reported to be effective in visceral leishmaniasis as well CL. The current study is designed to determine efficacy and safety of oral miltefosine for the treatment of anthroponotic cutaneous leishmaniasis (ACL) cases who were refractory to MA in Iran. Methodology/Principal findings: Miltefosine was orally administered for 27 patients with MA resistant ACL with approved L.tropica infection, at a dosage of ∼2.5 mg/kg daily for 28 days. Patients were evaluated on day 14 and 28, as well as 3, 6 and 12 month post treatment follow up sessions. Laboratory data were performed and repeated at each visit. Data were analyzed using SPSS version 17. Twenty-seven patients including 16 men (59.25%) and 11 women (40.74%) with mean age of 28.56 ± 4.8 (range 3–54 years old) were enrolled. Total number of lesions were 42 (1–4 in each patient). Most of lesions were on face (76.19%). Mean lesions’ induration size was 2.38 ± 0.73 cm at the base-line which significantly decreased to1.31 ± 0.58 cm and 0.61 ±0.49 cm after 14 and 28 days of therapy, respectively (p value <0.05). At 12-months follow-up post treatment, 22 patients had definite/partial cure (81.48%) including 17 definitely cured patients, corresponding to a cure rate of 68% on per protocol analysis, and 62.96% according to intention to treat analysis. Recurrence of lesion was only occurred in one patient (3.70%). Nausea was the most subjective complication during the therapy (33.33%). Conclusion: Oral miltefosine could be an effective alternative for the treatment of MA-resistant ACL.
- Open Access
- 1 March 2021
- Vol. 24 (1) , 40-45
Comparison of serum zinc level in acute improved and chronic cutaneous leishmaniasis
- 1 March 2021
- Vol. 24 (1) , 40-45
Open AccessComparison of serum zinc level in acute improved and chronic cutaneous leishmaniasis
- Open Access
- 24 November 2020
- Published by Wiley in Clinical Case Reports
- Vol. 9 (1) , 133-136
Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid‐induced immunosuppression
Clinicians should always consider rare, atypical, and opportunistic infections in patients undergoing long‐term systemic corticosteroid therapy. Diagnosis needs further evaluations and special consideration.
- 24 November 2020
- Published by Wiley in Clinical Case Reports
- Vol. 9 (1) , 133-136
Open AccessUnusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid‐induced immunosuppression
Clinicians should always consider rare, atypical, and opportunistic infections in patients undergoing long‐term systemic corticosteroid therapy. Diagnosis needs further evaluations and special consideration.